Targeting matrix metalloproteinases and endothelial cells with a fusion peptide against tumor

Cancer Research

Volumn 67, Issue 15, 2007, Pages 7295-7300

  Zou, Yufei ^a   Chen, Yahui ^a   Jiang, Yongqiang ^a,c   Gao, Jin ^b   Gu, Jun ^a  

^a PEKING UNIVERSITY   (China)

^b INSTITUTE OF BIOPHYSICS   (China)

^c BEIJING INSTITUTE OF MICROBIOLOGY AND EPIDEMIOLOGY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

CYSTEINYLTHREONYLTHREONYLHISTIDYLTRYPTOPHYLGLYCYLPHENYLALANYL THREONYLLEUCYLCYSTEINE; HYBRID PROTEIN; KRINGLE 5 PROTEIN; MATRIX METALLOPROTEINASE; PEPTIDE FRAGMENT; PLASMINOGEN; PROTEIN; RK 5; UNCLASSIFIED DRUG;

ANGIOGENESIS; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER INHIBITION; CANCER SURVIVAL; CELL MIGRATION; CELL PROLIFERATION; CONTROLLED STUDY; ENDOTHELIUM CELL; ENZYME ACTIVITY; GENE DELIVERY SYSTEM; IN VIVO STUDY; KRINGLE DOMAIN; LUNG CANCER; MALE; METASTASIS; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN TARGETING; SURVIVAL TIME; TUMOR GROWTH; YEAST;

ANGIOGENESIS INHIBITORS; ANIMALS; CARCINOMA, LEWIS LUNG; CELL MOVEMENT; CELL PROLIFERATION; ENDOTHELIUM, VASCULAR; HUMANS; KRINGLES; MALE; MATRIX METALLOPROTEINASES; MICE; MICE, INBRED C57BL; NEOPLASM METASTASIS; OLIGOPEPTIDES; PLASMINOGEN; RECOMBINANT FUSION PROTEINS; SACCHAROMYCES CEREVISIAE; SURVIVAL RATE; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 34547617698     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-06-3920     Document Type: Article

References (30)

1. Folkman J. Tumor angiogenesis: therapeutic implications. N Engl J Med 1971;285:1182-6.
2. Bussolino F, Mantovani A, Persico G. Molecular mechanisms of blood vessel formation. Trends Biochem Sci 1997;22:251-6.
3. Keck PJ, Hau ser SD, Krivi G, et al. Vascular permeability factor, an endothelial cell mitogen related to PDGF. Science 1989;246:1309-12.
4. Shweiki D, Itin A, Soffer D, Keshet E. Vascular endothelial growth factor induced by hypoxia may mediate hypoxia-initiated angiogenesis. Nature 1992;359:843-5.
5. Dawson DW, Volpert OV, Gillis P, et al. Pigment epithelium-derived factor: a potent inhibitor of angiogenesis. Science 1999;285:245-8.
6. Jimenez B, Volpert OV. Mechanistic insights on the inhibition of tumor angiogenesis. J Mol Med 2001;78:663-72.
7. Schweigerer L, Neufeld G, Mergia A, Abraham JA, Fiddes JC, Gospodarowicz D. Basic fibroblast growth factor in human rhabdomyosarcoma cells: implications for the proliferation and neovascularization of myoblast-derived tumors. Proc Natl Acad Sci U S A 1987;84:842-6.
8. Hotchkiss KA, Ashton AW, Schwartz EL. Thymidine phosphorylase and 2-deoxyribose stimulate human endothelial cell migration by specific activation of the integrins α5β1 and αVβ3. J Biol Chem 2003;278:19272-9.
9. Shan S, Robson ND, Cao Y, et al. Responses of vascular endothelial cells to angiogenic signaling are important for tumor cell survival. FASEB J 2004;18:326-8.
10. Zhang L, Yang N, Park JW, et al. Tumor-derived vascular endothelial growth factor up-regulates angiopoietin-2 in host endothelium and destabilizes host vasculature, supporting angiogenesis in ovarian cancer. Cancer Res 2003;63:3403-12.
11. Bode W, Maskos K. Structural basis of the matrix metalloproteinases and their physiological inhibitors, the tissue inhibitors of metalloproteinases. Biol Chem 2003;384:863-72.
12. Gondi CS, Lakka SS, Yanamandra N, et al. Adenovirus-mediated expression of antisense urokinase plasminogen activator receptor and antisense cathepsin B inhibits tumor growth, invasion, and angiogenesis in gliomas. Cancer Res 2004;64:4069-77.
13. Mott JD, Werb Z. Regulation of matrix biology bymatrix metalloproteinases. Curr Opin Cell Biol 2004;16:558-64.
14. Brew K, Dinakarpandian D, Nagase H. Tissue inhibitors of metalloproteinases: evolution, structure and function. Biochim Biophys Acta 2000;1477:267-83.
15. O'Reilly MS, Holmgren L, Shing Y, et al. Angiostatin: a novel angiogenesis inhibitor that mediates the suppression of metastases by a Lewis lung carcinoma. Cell 1994;79:315-28.
16. O'Reilly MS, Boehm T, Shing Y, et al. Endostatin: an endogenous inhibitor of angiogenesis and tumor growth. Cell 1997;88:277-85.
17. Good DJ, Polverini PJ, Rastinejad F, et al. A tumor suppressor-dependent inhibitor of angiogenesis is immunologically and functionally indistinguishable from a fragment of thrombospondin. Proc Natl Acad Sci U S A 1990;87:6624-8.
18. Cao Y, Chen A, An SS, Ji RW, Davidson D, Llinas M. Kringle 5 of plasminogen is a novel inhibitor of endothelial cell growth. J Biol Chem 1997;272:22924-8.
19. Lu H, Dhanabal M, Volk R, et al. Kringle 5 causes cell cycle arrest and apoptosis of endothelial cells. Biochem Biophys Res Commun 1999;258:668-73.
20. Zhang D, Kaufman PL, Gao G, Saunders RA, Ma JX. Intravitreal injection of plasminogen kringle 5, an endogenous angiogenic inhibitor, arrests retinal neovascularization in rats. Diabetologia 2001;44:757-65.
21. Zhou Y, Zheng Q, Gao J, Gu J. High level expression of kringle 5 fragment of plasminogen in Pichia pastoris. Biotechnol Lett 2005;27:167-71.
22. Koivunen E, Arap W, Valtanen H, et al. Tumor targeting with a selective gelatinase inhibitor. Nat Biotechnol 1999;17:768-74.
23. Davidson DJ, Haskell C, Majest S, et al. Kringle 5 of human plasminogen induces apoptosis of endothelial and tumor cells through surface-expressed glucose-regulated protein 78. Cancer Res 2005;65:4663-72.
24. Perri SR, Nalbantoglu J, Annabi B, et al. Plasminogen kringle 5-engineered glioma cells block migration of tumor-associated macrophages and suppress tumor vascularization and progression. Cancer Res 2005;65:8359-65.
25. Torimura T, Ueno T, Kin M, et al. Gene transfer of kringle 1-5 suppresses tumor development and improves prognosis of mice with hepatocellular carcinoma. Gastroenterology 2006;130:1301-10.
26. Murphy G, Crabbe T. Gelatinases A and B. Methods Enzymol 1995;248:470-84.
27. Hotz HG, Hines OJ, Hotz B, Foitzik T, Buhr HJ, Reber HA. Evaluation of vascular endothelial growth factor blockade and matrix metalloproteinase inhibition as a combination therapy for experimental human pancreatic cancer. J Gastrointest Surg 2003;7:220-7; discussion 227-8.
28. Somlyo AV, Bradshaw D, Ramos S, Murphy C, Myers CE, Somlyo AP. Rho-kinase inhibitor retards migration and in vivo dissemination of human prostate cancer cells. Biochem Biophys Res Commun 2000;269:652-9.
29. London CA, Sekhon HS, Arora V, Stein DA, Iversen PL, Devi GR. A novel antisense inhibitor of MMP-9 attenuates angiogenesis, human prostate cancer cell invasion and tumorigenicity. Cancer Gene Ther 2003;10:823-32.
30. Shim BS, Kang BH, Hong YK, et al. The kringle domain of tissue-type plasminogen activator inhibits in vivo tumor growth. Biochem Biophys Res Commun 2005;327:1155-62.